Laurie and Tim made dinner. Chicken enchilades and Lemon Blueberry Poppyseed Scones. Yum!

Raoul came in to do Rich's hair.

Dominick gave a classical piano concert for Rich via Skype.


A Day of Games

January 30, 2010

Yesterday we went down to Mesa and played games and laughed a lot.

Phase 10 and Craps! Rich won Phase 10!

Help Today

January 28, 2010

Dinner and a visit. Viki brought over seafood chowder today, Yum!

Linda came over today to help out and visit.

Shane came to work on Rich's back today.

A Visit and Dinner!

January 27, 2010

Kate brought over homemade potato soup with heartwarming sayings on them.

A Visit

January 27, 2010

Dad, Evan, Mom, My Dad and Me

The Tongue Drive system’s technology was developed for individuals with paralysis caused by spinal cord injury, stroke or Lou Gehrig’s disease.

To read the complete article, please click on this link:

There was a lot of reminiscing, shared laughter and good times last week when Rich’s Dad Stan came to visit from New York, his sister Liz came to visit from Massachusetts, cousins Cynthia and John came to visit from Yuma, and longtime Mackney family friend Mary came to visit from Los Angeles.

Mary and Rich

Stan, Mary, Liz and Rich

Stan, Cynthia, John and Rich

Master caregiver Evan and Stan

The U.S. Food and Drug Administration (FDA) has approved Covington, La.-based TCA Cellular Therapy’s adult stem cell protocol to conduct Phase I clinical trials to assess the safety of a proposed treatment for amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s disease).

This is the second FDA-approved protocol for the treatment of ALS using stem cells in the country, and the first using adult stem cells from the same patient.

Click on this link to read the complete article:

Rockville, Md.-based Neuralstem, Inc. (CUR) said on January 21 that the first amyotrophic lateral sclerosis (ALS) patient was treated with its spinal cord stem cells at the Emory ALS Center at Emory University, in Atlanta, Ga.

Up to 18 patients are expected to be treated in this first U.S. clinical trial to evaluate human neural stem cells for the treatment of ALS, also known as Lou Gehrig’s disease.

ALS affects roughly 30,000 people in the U.S., with about 5,600 new diagnoses per year, according to the ALS Association.

To read the complete article, please click on the following link:

Singapore scientists have discovered that a new combination of transcription factors can reprogram differentiated cells into induced pluripotent stem (iPS) cells.
To read the full story, please click on the following link:

%d bloggers like this: